| Thyroid dysfunction during chronic amiodarone therapy. | |
| | |
MedLine Citation:
|
PMID: 3794094 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Clinical and laboratory features of 99 patients receiving long-term amiodarone therapy were analyzed to determine which individuals may be at a high risk for developing amiodarone-induced thyroid dysfunction. The group of 68 men and 31 women was followed up for an average of 27 months (range 3 to 60). There were no differences in age, sex, dose of amiodarone, type or severity of underlying heart disease or baseline serum thyroxine levels in patients who developed hypothyroidism (n = 32) or hyperthyroidism (n = 5) or remained euthyroid (n = 62). Baseline serum thyrotropin levels were statistically higher in patients who became hypothyroid, but there was considerable overlap with the other patient groups. Serum reverse triiodothyronine (reverse T3), which has been suggested to be a marker of amiodarone efficacy, correlated directly with serum thyroxine levels, and was not an independent variable. There was no pattern to the time course for development of thyroid dysfunction, which occurred in 49% of those followed up and developed as early as 1 month or, in one individual, as late as after 3 years of amiodarone therapy. There are few guidelines for replacement therapy in patients with amiodarone-induced hypothyroidism. L-thyroxine dosage was adjusted cautiously in these high risk individuals to achieve serum thyroxine levels within the reference range of euthyroid individuals taking amiodarone: the mean dosage required was 136 micrograms/day. Normalization of serum thyrotropin (TSH) would have required doses of L-thyroxine that were judged to be excessively high.(ABSTRACT TRUNCATED AT 250 WORDS) |
| | |
Authors:
|
S G Albert; L E Alves; E P Rose |
Related Documents
:
|
18410374 - Hypokalemic thyrotoxic periodic paralysis: clinical characteristics and predictors of r... 2908034 - Clinical experience with a radioreceptor assay for tsh-binding inhibiting immunoglobuli... 17201804 - Unmasking of central hypothyroidism following growth hormone replacement in adult hypop... 18073314 - Type 2 deiodinase polymorphism (threonine 92 alanine) predicts l-thyroxine dose to achi... 17651094 - Stroke-work loss underestimates hemodynamic significance of aortic stenosis in patients... 20150584 - Refractory ascites due to portal hypertension in autosomal dominant polycystic kidney d... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Journal of the American College of Cardiology Volume: 9 ISSN: 0735-1097 ISO Abbreviation: J. Am. Coll. Cardiol. Publication Date: 1987 Jan |
Date Detail:
|
Created Date: 1987-02-02 Completed Date: 1987-02-02 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8301365 Medline TA: J Am Coll Cardiol Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 175-83 Citation Subset: AIM; IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Amiodarone / adverse effects*, therapeutic use Arrhythmias, Cardiac / drug therapy Cholesterol / blood Female Humans Hyperthyroidism / chemically induced* Hypothyroidism / chemically induced* Male Risk Thyroid Function Tests Thyrotropin / blood Thyroxine / blood |
| Chemical | |
Reg. No./Substance:
|
1951-25-3/Amiodarone; 57-88-5/Cholesterol; 7488-70-2/Thyroxine; 9002-71-5/Thyrotropin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Value of Holter monitoring in predicting long-term efficacy and inefficacy of amiodarone used alone ...
Next Document: Alterations in left ventricular diastolic function with doxorubicin therapy.